Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Incorporated (NYSE: TFX) is a leading global provider of specialty medical devices for critical care and surgical procedures. Headquartered in Wayne, Pennsylvania, Teleflex employs approximately 12,000 people worldwide and serves healthcare providers in more than 150 countries.
The company’s diverse product portfolio spans across several key segments: vascular access, interventional, anesthesia, surgical, interventional urology, original-equipment manufacturing, and others. These segments collectively cover a wide range of medical needs, from complex surgical interventions to everyday critical care requirements.
Teleflex’s vascular access segment, contributing 24% to 2023 sales, includes innovative solutions for secure and reliable bloodstream access. The interventional segment, accounting for 17%, focuses on cutting-edge devices for minimally invasive procedures. Anesthesia and surgical segments, with 13% and 14% of sales respectively, offer advanced tools and technologies to improve patient outcomes during surgeries.
The company’s interventional urology segment, noted for its UroLift™ System, addresses benign prostatic hyperplasia (BPH) with minimally invasive solutions that preserve patient quality of life. Original-equipment manufacturing and other segments contribute 11% and 10% of sales respectively, underscoring Teleflex’s broad manufacturing capabilities and diverse product offerings.
Teleflex's geographic exposure is primarily in the United States, which generates 60% of its revenue, with international markets contributing the remainder. The company’s global reach and diverse product lines highlight its significant impact on the healthcare industry worldwide.
In recent years, Teleflex has achieved notable success with a 6.5% constant currency revenue growth in 2023, driven by the expansion of its geographic presence and the launch of innovative new products. The company has strategically acquired Palette Life Sciences AB, enhancing its portfolio and operational efficiencies.
Teleflex remains committed to its mission of providing solutions that improve outcomes and enhance safety for patients and healthcare providers. By leveraging purpose-driven innovation, Teleflex continues to address unmet clinical needs and advance healthcare technologies.
For more information about Teleflex and its comprehensive product offerings, please visit teleflex.com.
Teleflex Incorporated (NYSE: TFX) is participating in the Pocono Raceway NASCAR event from July 22-24, 2022, to raise awareness about benign prostatic hyperplasia (BPH). BPH affects over 14 million men, causing symptoms like urinary frequency and urgency. The company emphasizes the importance of routine screenings, especially after many delayed medical care during the COVID-19 pandemic. At the event, Teleflex will feature the UroLift® System, a minimally invasive treatment for BPH, and host patient ambassadors to share personal experiences.
Teleflex Incorporated (NYSE: TFX) is set to host a conference call on July 28, 2022, at 8:00 a.m. ET to discuss its second quarter financial results and provide an operational update. Participants can pre-register using a provided link or access the live audio webcast on the company’s website. An audio replay will be available after the call. Teleflex is a global provider of medical technologies aimed at improving health outcomes, with products in various medical fields, including vascular access and anesthesia.
Teleflex announced promising findings at the 37th Annual European Association of Urology Congress regarding its UroLift System for treating benign prostatic hyperplasia (BPH). Key results showed that 79% of over 300 subjects reported a reduction in their IPSS symptom severity 12 months post-treatment. Furthermore, symptom improvement was independent of prostate size or shape. The study also highlighted that patients treated with UroLift required significantly fewer prescriptions post-surgery compared to those undergoing more invasive procedures.
Teleflex Incorporated (NYSE: TFX) announced the first patient enrolled in the MANTA Ultra Study, aimed at assessing the safety of the MANTA® Vascular Closure Device using ultrasound guidance during elective TAVR procedures. This prospective study will involve up to 150 patients across 15 sites in the US and Canada, focusing on reducing access site complications associated with large bore procedures. Key endpoints include major and minor vascular complications within 30 days, along with various effectiveness measures. The study could enhance procedural flexibility for surgeons.
Teleflex Incorporated (NYSE: TFX) announced the launch of its Arrow Pressure Injectable Midline Catheter in Europe, the Middle East, and Africa. This new catheter, featuring brightly colored hubs to enhance clinician identification and minimize infusion errors, is available in 1-lumen and 2-lumen configurations. Key features include a TAPERFREE design to reduce venous stasis and procedural efficiency enhancements. The device allows for pressure injection up to 5 mL/second, improving patient care and reducing delays in diagnostics.
Teleflex (NYSE: TFX) provided a business update during its 2022 Analyst & Investor Day in New York City on May 20, 2022. The company outlined its growth strategy for 2023-2025, targeting a compounded annual constant currency revenue growth rate of 6-7%. Teleflex expects adjusted earnings per share to increase to between $13.70 and $14.30 for 2022. The company anticipates generating free cash flow of at least $1.7 billion from 2023 to 2025, with a focus on margin improvement and strategic acquisitions. The full year revenue growth for 2022 is projected to be between 2.3% and 3.8%.
Teleflex Incorporated has announced the National Medical Products Administration (NMPA) approval for its UroLift® System in China, aimed at treating benign prostatic hyperplasia (BPH). This minimally invasive treatment offers symptom relief with same-day outpatient procedures. CEO Liam Kelly highlighted this as a critical step in the company's international expansion, providing treatment options for over 25 million men in China diagnosed with BPH. The company anticipates commercialization by Q4 2022.
Teleflex (NYSE: TFX) has received Health Canada approval for the MANTA® Vascular Closure Device, marking a significant regulatory milestone. This device is designed for large bore femoral arterial access site closure and enhances the availability of innovative solutions for Canadian clinicians. Since its launch in 2016, over 100,000 patients have been treated with the MANTA® Device worldwide. The SAFE MANTA IDE Clinical Trial demonstrated the device's effectiveness in achieving rapid hemostasis without the need for pre-closure, enabling quicker and safer procedures.
Teleflex Incorporated (NYSE: TFX) announced the U.S. launch of its UroLift® 2 System and UroLift ATC® System for treating benign prostatic hyperplasia (BPH). These advancements were showcased at the 2022 American Urological Association (AUA) annual meeting in New Orleans from May 13-16. The UroLift 2 offers an ergonomic design and improved workflow, while the UroLift ATC enhances treatment options for patients with obstructive middle lobes. Teleflex will host a special presentation on these innovations at booth #323 during the event.
FAQ
What is the current stock price of Teleflex (TFX)?
What is the market cap of Teleflex (TFX)?
What does Teleflex Incorporated do?
Where is Teleflex Incorporated headquartered?
How many people does Teleflex employ?
What are the main segments of Teleflex's business?
What percentage of Teleflex’s revenue comes from the United States?
What recent acquisitions has Teleflex made?
What is the UroLift™ System?
What was Teleflex's revenue growth in 2023?
How can one access Teleflex's investor conference calls?
What is the mission of Teleflex Incorporated?
